Two-year phase III trial to investigate the long-term cardiovascular safety of tesofensine.
Phase of Trial: Phase III
Latest Information Update: 31 May 2011
At a glance
- Drugs Tesofensine (Primary)
- Indications Obesity
- Focus Adverse reactions; Registrational
- 31 May 2011 New trial record
- 26 May 2011 The design of the pivotal phase III programme for tesofensine was revised based on feedback from the US FDA and the EMA.